These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 20205108)

  • 1. Does cellular glucose transport respond to a controlled diet and sulfonylurea therapy in type 2 diabetes mellitus?
    Tatoń J; Piatkiewicz P; Czech A
    Endokrynol Pol; 2010; 61(1):75-81. PubMed ID: 20205108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular glucose transport and glucotransporter 4 expression as a therapeutic target: clinical and experimental studies.
    Czech A; Piatkiewicz P; Tatoń J
    Arch Immunol Ther Exp (Warsz); 2009; 57(6):467-73. PubMed ID: 19885647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular glucose transport disturbances as a marker of the pre-diabetic state - pathogenetic and clinical significance of the assessment of GLUT4 expression.
    Bernat-Karpińska M; Czech A; Piatkiewicz P; Wierzbicki P; Górski A
    Endokrynol Pol; 2010; 61(3):269-74. PubMed ID: 20602301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular physiology of cellular glucose transport - a potential area for clinical studies in diabetes mellitus.
    Tatoń J; Piatkiewicz P; Czech A
    Endokrynol Pol; 2010; 61(3):303-10. PubMed ID: 20602306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-insulin-dependent diabetes: 10-year outcome in relation to initial response to diet and subsequent sulfonylurea therapy.
    Sönksen PH; Lowy C; Perkins JR; Lim HS
    Diabetes Care; 1984; 7 Suppl 1():59-66. PubMed ID: 6376030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
    Kabadi UM; Kabadi MU
    J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
    Diabetes; 1995 Nov; 44(11):1249-58. PubMed ID: 7589820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular glucose transport disturbances in the pathogenesis and therapy of type 2 diabetes mellitus.
    Czech A; Tatoń J; Piatkiewicz P
    Endokrynol Pol; 2010; 61(3):292-302. PubMed ID: 20602305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus.
    Kolterman OG
    Am J Med; 1985 Sep; 79(3B):23-33. PubMed ID: 3931459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
    Tattersall RB
    Journ Annu Diabetol Hotel Dieu; 1984; ():183-91. PubMed ID: 6443219
    [No Abstract]   [Full Text] [Related]  

  • 13. [Combined insulin and sulfonylurea treatment in diabetes mellitus].
    Ravina A; Minuhin O
    Harefuah; 1986 Jan; 110(1):11-4. PubMed ID: 3514394
    [No Abstract]   [Full Text] [Related]  

  • 14. [Delayed sulfonylurea resistance in non-insulin-dependent diabetes mellitus].
    Farkas K; Jermendy G; Somogyi A
    Orv Hetil; 1997 Nov; 138(48):3031-5. PubMed ID: 9441264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sulfonylurea drug--a new sulfonylurea drug for type 2 diabetes].
    Toyota T
    Nihon Rinsho; 1999 Mar; 57(3):695-701. PubMed ID: 10199156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.
    Iwasaki Y; Kondo K; Hasegawa H; Oiso Y
    Diabetes Res; 1994; 25(3):129-37. PubMed ID: 7671552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients.
    Rivellese AA; Patti L; Romano G; Innelli F; Di Marino L; Annuzzi G; Iavicoli M; Coronel GA; Riccardi G
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4188-92. PubMed ID: 11095452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and traditional treatment of glycemia in NIDDM.
    Bloomgarden ZT
    Diabetes Care; 1996 Mar; 19(3):295-9. PubMed ID: 8742586
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus.
    Prigeon RL; Jacobson RK; Porte D; Kahn SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3295-8. PubMed ID: 8784086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose transport in human peripheral blood lymphocytes influenced by type 2 diabetes mellitus.
    Piatkiewicz P; Czech A; Tatoń J
    Arch Immunol Ther Exp (Warsz); 2007; 55(2):119-26. PubMed ID: 17417692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.